【摘要】 目的:研究沙库巴曲/缬沙坦(Sac/Val)对高血压心脏病患者血压，心脏结构和不良反应等的影响。方法:于我院治疗的220例高血压心脏病患者被随机均分为Sac/Val组(接受Sac/Val治疗)和奥美沙坦组(接受奥美沙坦治疗),两组均随访1年。比较两组治疗前后一般临床资料、收缩压、舒张压、左室舒张末期内径(LVEDd)、左房内径(LAD)、血浆N基末端脑钠肽前体(NT-proBNP)水平及随访1年后主要不良心血管事件(MACE)率、因心衰住院率。结果:随访过程中，Sac/Val组失访13例，奥美沙坦组失访7例。与奥美沙坦组比较，治疗后，Sac/Val组LVEDd [(54.43±2.91)mm比(51.32±5.84)mm]、LAD[(42.51±3.13)mm比(40.02±2.89)mm]、血浆NT-proBNP水平[(2105.77±332.52)pg/ml比(1560.71±218.36) pg/ml]均显著降低(P均=0.001)。随访1年后，Sac/Val组MACE率(5.2%比13.6%)及因心衰住院率(2.1%比8.7%)均显著低于奥美沙坦组(P均<0.05)。结论:沙库巴曲/缬沙坦可显著改善高血压心脏病患者心脏结构，降低MACE率及因心衰住院率。更多还原

【Abstract】 Objective:To study influence of sacubitril/valsartan(Sac/Val) on blood pressure, cardiac structure, MACE etc. in patients with hypertensive heart disease. Methods: A total of 220 patients with hypertensive heart disease treated in our hospital were randomly and equally divided into Sac/Val group(received Sac/Val treatment) and olmesartan group(received olmesartan treatment). Both groups were followed up for one year. General clinical data, systolic blood pressure, diastolic blood pressure, left ventricular end-diastolic dimension(LVEDd), left atrial dimension(LAD) and plasma level of N-terminal pro-brain natriuretic peptide(NT-proBNP) before and after treatment and incidence rate of major adverse cardiovascular events(MACE) rate and heart failure(HF)-caused hospitalization rate during one-year follow-up were compared between two groups. Results:During follow-up, there were 13 cases lost in Sac/Val group and 7 cases lost in olmesartan group. Compared with olmesartan group, after treatment, there were significant reductions in LVEDd [(54.43±2.91) mm vs.(51.32±5.84)mm], LAD [(42.51±3.13)mm vs.(40.02±2.89)mm] and plasma NT-proBNP level [(2105.77±332.52)pg/ml vs.(1560.71±218.36) pg/ml] in Sac/Val group(P=0.001 all). After one-year follow-up, incidences rate of MACE(5.2% vs. 13.6%) and HF-caused hospitalization rate(2.1% vs. 8.7%) of Sac/Val group were significantly lower than those of olmesartan group(P<0.05 all). Conclusion:Sacubitril/valsartan can significantly improve cardiac structure, reduce incidence rates of MACE and HF-caused hospitalization rate in patients with hypertensive heart disease.更多还原